Parkinson's disease therapy developer Aspen Neuroscience (ASPE.US) sets IPO price at $15-17 per share, aiming to raise $150 million
Aspen Neuroscience has announced its IPO terms.
According to news from Zhihu Finance APP, Aspen Neuroscience, a clinical-stage biotechnology company developing stem cell therapies for Parkinson’s disease, announced its IPO terms on Monday. The San Diego, California-based company plans to issue 9.4 million shares at a price range of $15 to $17 per share, aiming to raise $150 million. Based on the midpoint of the proposed price range, Aspen Neuroscience’s fully diluted market value would be approximately $494 million.
Aspen Neuroscience is dedicated to developing autologous induced pluripotent stem cell (iPSC)-derived therapies for neurodegenerative diseases. Its lead product candidate, sasineprocel, is a single-dose cell therapy made from cells obtained from the patient’s own skin biopsy, designed to replace the dopaminergic neurons lost in Parkinson’s disease. The company is conducting an open-label Phase 1/2a clinical trial to evaluate the efficacy of sasineprocel. As of August 18, 2026, 15 patients have received dosing; according to FDA feedback, the company expects to dose patients in a Phase III trial in the second half of 2027. Sasineprocel has received FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations.
Aspen Neuroscience was founded in 2018 and plans to list on the Nasdaq under the symbol “ASPE”. Leerink Partners, Piper Sandler, Stifel, UBS Investment Bank, and Oppenheimer & Co. are serving as joint underwriters for the offering. Pricing is expected during the week of October 26, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Illinois Tool Works shares fall as quarterly revenue misses estimates
Merlin Names Chief Revenue Officer Mark Brunner President
BUZZ - Euronet shares fall due to third-quarter earnings missing expectations
U.S. durable goods orders in September posted the largest increase in five months, with AI investment supporting corporate equipment demand
U.S. durable goods orders rose by 1.8% month-on-month in September, marking the largest increase in five months and surpassing the previous upwardly revised figure of 0.1%, though slightly below the market expectation of 1.9%. Manufacturing demand further recovered, with broad gains in orders for aircraft, computers, machinery, and automobiles. Business equipment investment also remained strong, providing new support for U.S. economic growth in the third quarter.
